Kavakcioglu Yardimci, BernaOzgun Acar, OzdenSemiz, AsliSen, Alaattin2025-09-252025-09-2520211300-7467https://doi.org/10.5505/tjo.2020.2380https://search.trdizin.gov.tr/en/yayin/detay/505320/apatinib-sensitizes-human-breast-cancer-cells-against-navitoclax-and-venetoclax-despite-up-regulated-bcl-2-and-mcl-1-gene-expressionshttps://hdl.handle.net/20.500.12573/3311Ozgun Acar, Ozden/0000-0002-2910-6349; Sen, Alaattin/0000-0002-8444-376X; Kavakcioglu Yardimci, Berna/0000-0003-0719-9094OBJECTIVE Defects in apoptotic cell death which restrict the success of conventional cytotoxic therapies have pivotal roles in a number of pathological conditions including cancer. However, a novel drug class targeting pro-survival Bcl-2 protein family members has been developed with the understanding of the structures and interactions of Bcl-2 proteins. Within this new class, Bcl-2/Bcl-xL inhibitor Navitoclax and Bcl-2 specific inhibitor Venetoclax have been shown to demonstrate strong anticancer activities on several types of cancers. But their low affinity to other anti-apoptotic proteins limits their clinical usage. Here, we investigated the cytotoxic and apoptotic effects of Navitoclax/Venetoclax and their combinations with specific tyrosine kinase inhibitor Apatinib on estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cell lines. METHODS MTT assay was used for the evaluation of the inhibition of cancer cell proliferation. ELISA test and Quantitative real-time PCR assay was performed to determine the role of caspase-3, Bak, Bax, Bcl-2, Bcl-xL and Mcl-1 proteins in the inhibition of cell proliferation triggered by the tested agents. RESULTS We found that aggressive MDA-MB-231 cell line was more sensitive to all tested agents. Apatinib significantly enhanced Navitoclax/Venetoclax mediated inhibition of cell viability in both cancer cell lines despite up-regulation in the expression levels of Bcl-2 and Mcl-1 genes. We further demonstrated significant Bak/Bax and caspase-3 expression in less aggressive MCF-7 cells. CONCLUSION Our findings have impacts on Navitoclax/Venetoclax plus Apatinib based therapy for breast adenocarcinoma. On the other hand, further studies should be conducted to elucidate the mechanisms underlying synergistic effects of Navitoclax/Venetoclax plus Apatinib combinations.eninfo:eu-repo/semantics/openAccessApatinibApoptosis, Breast AdenocarcinomaCytotoxicityNavitoclaxVenetoclaxArticle10.5505/tjo.2020.23802-s2.0-85102437215